ANDA 77605, held by Barr Laboratories. Galantamine Hydrobromide.
As of Nov 21, 2026, ANDA 77605 (Galantamine Hydrobromide), held by Barr Laboratories, was first approved by FDA on Aug 28, 2008, with 6 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 28, 2008 | Original application | Approved |
| Galantamine HydrobromideEQ 4MG BASE · tablet;oral | Galantamine Hydrobromide | Rx |
| Galantamine HydrobromideEQ 8MG BASE · tablet;oral | Galantamine Hydrobromide | Rx |
| Galantamine HydrobromideEQ 12MG BASE · tablet;oral | Galantamine Hydrobromide | Rx |
| Feb 19, 2025 | Supplement 11Labeling · Standard review | Approved | None posted |
| Apr 28, 2016 | Supplement 9Labeling · Standard review | Approved | None posted |
| Nov 10, 2015 | Supplement 8Labeling · Standard review | Approved | None posted |
| Aug 12, 2014 | Supplement 7Labeling · Standard review | Approved | None posted |
| Jan 28, 2013 | Supplement 5Labeling · Standard review | Approved | None posted |
| Oct 11, 2012 | Supplement 4Labeling · Standard review | Approved | None posted |
| Aug 28, 2008 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters